ddSEQ™ Single-Cell 3′ RNA-Seq Kit and Omnition v1.1 Analysis Software Enable High-Quality and Affordable Single-Cell Transcription and Gene Expression to Support Molecular Biology, Oncology, and Drug Discovery Research

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the ddSEQ™ Single-Cell 3′ RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research.

Designed to be run on Bio-Rad’s droplet-based single-cell isolation system, the ddSEQ Cell Isolator, the ddSEQ Single-Cell 3′ RNA-Seq Kit delivers high-quality single-cell 3′ RNA-Seq libraries in a fast, efficient, and affordable workflow, allowing researchers to easily conduct single-cell gene expression and regulation analyses. The subsequent QC, analysis, and reporting of data generated from the ddSEQ Single-Cell 3′ RNA-Seq Kit is enabled by the accompanying Omnition v1.1 Analysis Software, a robust pipeline analysis tool. These valuable insights into single-cell transcription and gene expression support a broad range of research fields such as oncology, immunology, neurology, and stem cell biology.

“The new ddSEQ™ Single-Cell 3′ RNA-Seq Kit expands our NGS library preparation portfolio and is a further reflection of our commitment to provide researchers with innovative technologies to support molecular biology, oncology, and drug discovery research,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “Used with our ddSEQ Cell Isolator, the new kit and Omnition v1.1 Analysis Software presents a more cost-effective solution for single-cell transcription and gene expression studies, facilitating seamless integration into a broad spectrum of research applications and empowering research teams to undertake more experiments within the same budget.”

To learn more about the ddSEQ Single-Cell 3′ RNA-Seq Kit, visit www.bio-rad.com/ddSEQ3scRNA-SeqKit

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.